It is possible that the co-expression of prostasin in PD-L1-positive tumor cells may sensitize the cells to the anti-PD-L1 antibodies in immunotherapy targeting the PD-1/PD-L1 checkpoint. The gene discussed is PRSS8; the disease is neoplasm.